Rapport Therapeutics Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rapport Therapeutics's estimated annual revenue is currently $4.9M per year.(i)
  • Rapport Therapeutics's estimated revenue per employee is $64,243

Employee Data

  • Rapport Therapeutics has 76 Employees.(i)
  • Rapport Therapeutics grew their employee count by 33% last year.

Rapport Therapeutics's People

NameTitleEmail/Phone
1
Associate Director, AdministrationReveal Email/Phone
2
Sr. Administrative Business PartnerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M1-50%N/AN/A
#3
$5.1M3322%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M2-60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M290%N/AN/A
Add Company

What Is Rapport Therapeutics?

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

keywords:N/A

N/A

Total Funding

76

Number of Employees

$4.9M

Revenue (est)

33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.8M763%N/A
#2
$15.6M7612%N/A
#3
$7.5M76-1%N/A
#4
$10.6M76-11%$13M
#5
$13.7M7617%N/A